A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Patients will receive oral SKLB1028 for 28 days as a course of treatment, and then to
evaluate the side effects,tolerability and best dose for treating relapsed or refractory
acute myeloid leukemia With FLT3 Mutations.